INDIA at TCT 2025: TUXEDO-2 Trial Results
The TUXEDO-2 trial, led by Dr. Upendra Kaul, compared next-generation drug-eluting stents in diabetic patients.
In patients with diabetes and multivessel coronary artery disease (MVD), the ultra-thin biodegradable polymer sirolimus-eluting stent (Supraflex Cruz, SMT) demonstrated comparable procedural success and safety outcomes to the durable polymer everolimus-eluting stent (Xience, Abbott) when used alongside optimal medical therapy.
The TUXEDO-2 trial is the largest randomized trial to date comparing new-generation drug-eluting stents (DES) in an exclusively diabetic, high-risk population with extensive multivessel coronary disease.
Author's summary: TUXEDO-2 trial compares stents in diabetic patients.
More News
- Billie Eilish Calls on Billionaires to Do More for People in Need
- NewJeans to Appeal Label Contract Court Decision
- Libya voices deep concern over the situation in El Fasher, calls for immediate ceasefire in Sudan
- Humphrey School Students Host First-Ever Minneapolis Mayoral Forum
- 2025 NBA Cup TRACKER: Scores, Schedule, Standings
- Walton Student's Path to Senior Walk Leads to Success
- Fort Walton Beach lands on Expedia's top 10 destinations for 2026
- Brave New Films Presents “Gaza: Journalists Under Fire” - The New Paltz Oracle
- Stranger Things 5 trailer shows way more than we were ready for
- Dean Lewis Shares Statement Following Misconduct Allegations